ArticleNeuromolecular medicine2025
Knockdown of RUNX2 Attenuated A1 Astrocyte Overactivation, Brain Injury, and Cerebral Edema During Ischemic Stroke.
Article in Neuromolecular medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- The therapeutic potential of descending regulatory pathways from brain to bone in osteoporosis: focusing on the brain-bone axis.Frontiers in endocrinology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Although researchers began to unravel the potential significance of Runt-related transcription factor 2 (RUNX2) in some of neurological diseases, the role of RUNX2 in ischemic stroke remained unclear. Blood samples and clinical information were collected from stroke patients and control subjects. Besides, middle cerebral artery occlusion (MCAO) mice model and astrocytes oxygen-glucose deprivation/reperfusion (OGD/R) were established to simulate the pathological process of stroke in vivo and in vitro. Loss-of-function assay was used to assess the effect of RUNX2 on astrocytes function. HE staining and Nissl staining were used to examine the histopathological changes of brain tissues in mice. TTC staining was used to measure the cerebral infarct volume in mice. Morri's water maze test, the corner turn test, and the balance beam test were performed to evaluate neurobehavioral performances of mice. The results showed that the expression and serum content of RUNX2 were upregulated in stroke patients and mice. Knocking-down RUNX2 inhibited OGD/R-induced increases of proliferation and migration, while reversed the decrease of apoptosis in astrocytes. Moreover, RUNX2 knockdown also suppressed the inflammatory response in OGD/R-treated astrocytes and promoted the conversion of the reactive astrocyte phenotype from A1 to A2. The serum mRNA expression and level of RUNX2 were both notably increased in patients with cerebral edema. RUNX2 knockdown weakened cerebral edema and swelling of astrocytes. The results of HE staining and Nissl staining suggested that RUNX2 knockdown notably improved neuronal damage in the brain tissues of MCAO mice and also improved the injured performance of MCAO stroke mice in the behavioral test. In conclusion, RUNX2 expression was upregulated during the pathological progression of ischemic stroke. Furthermore, the knockdown of RUNX2 alleviated OGD/R-induced astrocytes activation and swelling, while inhibiting the polarization and inflammatory response in astrocytes. More importantly, RUNX2 interference also improved neuronal damage, cerebral edema, and neurobehavioral performances of MCAO mice.
Indexed as
Identifiers
40576866What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.